The availability of biosimilars to treat inflammatory diseases has generated concern about changing patients from a bio-originator to its biosimilar to save costs. Studies published in 2019 support the effectiveness and safety of ‘nonmedical switching’ and highlight the benefits of communicating information about biosimilars to patients in a positive light.

中文翻译：

---

克服炎性关节炎中生物仿制药的障碍。

生物仿制药可用于治疗炎症性疾病，引起了人们的关注，他们希望将患者从生物发起者改为其生物仿制药以节省成本。2019年发表的研究证明了``非医疗转换''的有效性和安全性，并强调了积极向患者传达有关生物仿制药信息的好处。